Estrogen replacement therapy after endometrial cancer: A survey of physicians' prescribing practice

Climacteric

Volumn 13, Issue 3, 2010, Pages 271-277

  Hancke, K ^a,b   Foeldi, M ^a   Zahradnik, H P ^a   Gitsch, G ^a   Gilbert, L ^c   Denschlag, D ^a,c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

E ndometrial cancer; Estrogen replacement therapy; Hormone replacement therapy; Prescribing practice; Survey

Indexed keywords

ESTROGEN; ISOFLAVONE DERIVATIVE; PHYTOESTROGEN; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; DISEASE SEVERITY; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; GERMANY; HEALTH SURVEY; HIGH RISK PATIENT; HOT FLUSH; HUMAN; MENOPAUSAL SYNDROME; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE;

ADENOCARCINOMA; ATTITUDE OF HEALTH PERSONNEL; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; GERMANY; HOT FLASHES; HUMANS; LIBIDO; MENOPAUSE; PHYSICIAN'S PRACTICE PATTERNS; PHYTOESTROGENS; QUESTIONNAIRES; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS;

EID: 77951864380     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697130903131338     Document Type: Article

References (25)

1. Krebs in Deutschland. 5. Überarbeitete, aktualisierte Ausgabe. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. und das RKI. Saarbrücken, 2006
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30
3. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984;64:417-420
4. Gallicchio L, Whiteman MK, Tomic D, et al. Type of menopause, patterns of hormone therapy use, and hot flashes. Fertil Steril 2006;85:1432-1440
5. Grady D. Clinical practice. Management of menopausal symptoms. N Engl J Med 2006;355:2338-2347
6. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291: 1701-1712
7. Creasman WT, Henderson D, Hinshaw W, et al. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326-330
8. Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990;36:189-191
9. Chapman JA, DiSaia PJ, Osann K, et al. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996;175:1195-1200
10. Suriano KA, McHale M, McLaren CE, et al. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 2001;97:555-560
11. Barakat RR, Bundy BN, Spirtos NM, et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2006;24:587-592
12. Holinka CF, Hata H, Kuramoto H, et al. Responses to estradiol in a human endometrial adenocarcinoma cell line (Ishikawa). J Steroid Biochem 1986;24:85-89 (Pubitemid 16047761)
13. Farnell YZ, Ing NH. The effects of estradiol and selective estrogen receptor modulators on gene expression and messenger RNA stability in immortalized sheep endometrial stromal cells and human endometrial adenocarcinoma cells. J Steroid Biochem Mol Biol 2003;84:453-461
14. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288: 321-333
15. Huot L, Couris CM, Tainturier V, et al. Trends in HRT and anti-osteoporosis medication prescribing in a European population after the WHI study. Osteoporos Int 2008;19:1047-1054
16. Thunell L, Milsom I, Schmidt J, et al. Scientific evidence changes prescribing practice - a comparison of the management of the climacteric and use of hormone replacement therapy among Swedish gynaecologists in 1996 and 2003. BJOG 2006;113:15-20
17. Buist DS, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004;104(5): 1042-1050
18. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057-2071
19. Stephenson J. FDA orders estrogen safety warnings: agency offers guidance for HRT use. JAMA 2003;289: 537-538
20. ACOG committee opinion. Hormone replacement therapy in women treated for endometrial cancer. Number 234, May 2000 (replaces number 126, August 1993). Int J Gynaecol Obstet 2001;73:283-284
21. Skouby SO, Barlow D, Samsioe G, et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) statements on postmenopausal hormonal therapy. Maturitas 2004;48:19-25
22. Skouby SO, Al Azzawi F, Barlow D, et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 2005;51:8-14
23. Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause 2004;11:589-600
24. SOGC clinical practice guidelines. The detection and management of vaginal atrophy. Number 145, May 2004. Int J Gynaecol Obstet 2005;88:222-228
25. ACOG committee opinion. Tamoxifen and endometrial cancer. Int J Gynaecol Obstet 2001;73:77-79